About: Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 November 1999

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в листопаді 1999 (uk) im November 1999 veröffentlichter wissenschaftlicher Artikel (de) scientific article published on 01 November 1999 (en) artículu científicu espublizáu en payares de 1999 (ast)
publication date	wds:Q73091505-556790EC-BEEB-4741-9CB1-9A0DC3261148
publication date	1999-11-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q73091505-96B93A56-4D90-42C5-855F-C47750B16B24
language of work or name	English
author name string	wds:Q73091505-3CD74186-8322-4546-8943-0C8BA8F48E8B wds:Q73091505-3F566EFF-2204-4728-94DB-9760FC1E1CFF wds:Q73091505-3F63E80A-C11B-4C3D-94FD-40F2A4FC2C79 wds:Q73091505-81013468-EEAC-43CB-899D-3DAC0C0A7061 wds:Q73091505-8379C751-FA47-4E2B-B9E9-C037822B8364 wds:Q73091505-91F93856-0799-4C5C-B8A8-485269AA9AE9 wds:Q73091505-AF1852B7-CB6F-42E3-93E0-E60AD4CF4868 wds:Q73091505-B4D07D86-6D0E-4067-A9A5-F3C8E8AAF4A1 wds:Q73091505-D4632FB4-FC01-409C-8B26-C83F3CB882C5 wds:Q73091505-D9959491-DD41-4CAD-A15F-CEBD89A52185 wds:Q73091505-EA2D5173-6787-42CF-B352-5375DF712D65 wds:Q73091505-F18523C5-6440-4AF4-94C5-E1FCFF451FCA wds:Q73091505-F32A93B1-0630-4CA1-AA2E-F6CBBC43E0A3 wds:Q73091505-F814AA57-B736-4AB4-AC9C-1F40C18411F3 wds:Q73091505-FC5258F7-EA5F-4306-A258-C6D053692831
author name string	D A Baker T A Smolarek J A Davis M J Morin L D Arnold M P Vaidya J D Moyer K K Iwata E G Barbacci K E Tsaparikos J L Doty D E Sloan D M Savage L R Pustilnik V A Pollack
rdfs:label	Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice (en) Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice (nl)
skos:prefLabel	Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice (en) Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice (nl)
name	Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice (en) Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice (nl)
title	wds:Q73091505-DF3BE444-8018-4689-8F77-7638D0DE69EF
title	Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice (en)
page(s)	wds:Q73091505-EB75E195-A605-4AC3-AE09-B86C28351FA2
page(s)	739-748
instance of	wds:Q73091505-361009AB-B44A-49C4-A127-790E665DCC1B
instance of	scholarly article
PubMed ID	wds:Q73091505-887725EC-11DA-47CD-B019-EBDE9E029CC7
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/10525095
PubMed ID	10525095
published in	wds:Q73091505-04AE27E2-9622-42E3-82A7-D0BD07A416CF
published in	Journal of Pharmacology and Experimental Therapeutics
issue	wds:Q73091505-F056AB61-EF1E-493B-8A4A-872BD225C148
volume	wds:Q73091505-E7F0D076-1746-41D3-BDCA-9B302A416568
issue	2
volume	291
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q73091505
is cites work of	Cisplatin-Based Chemotherapy Options for Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck EGF receptor inhibitor erlotinib as a potential pharmacological prophylaxis for posterior capsule opacification EGFR inhibition induces proinflammatory cytokines via NOX4 in HNSCC. Inhibition of doxorubicin-induced HER3-PI3K-AKT signalling enhances apoptosis of ovarian cancer cells. Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma The ERBB network: at last, cancer therapy meets systems biology. The autophagy inhibitor chloroquine overcomes the innate resistance of wild-type EGFR non-small-cell lung cancer cells to erlotinib Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors Probing the probes: fitness factors for small molecule tools Erlotinib in the treatment of advanced pancreatic cancer Novel agents for the prevention of breast cancer: targeting transcription factors and signal transduction pathways A phase II study of gefitinib, 5-fluorouracil, leucovorin, and oxaliplatin in previously untreated patients with metastatic colorectal cancer Targeted inhibition of kinases in cancer therapy The promise of anti-ErbB3 monoclonals as new cancer therapeutics Addition of bevacizumab enhances antitumor activity of erlotinib against non-small cell lung cancer xenografts depending on VEGF expression Dual inhibition of epidermal growth factor receptor and insulin-like growth factor receptor I: reduction of angiogenesis and tumor growth in cutaneous squamous cell carcinoma Biochemical mechanisms of resistance to small-molecule protein kinase inhibitors EGFR inhibitor erlotinib delays disease progression but does not extend survival in the SOD1 mouse model of ALS Experimental approaches for the treatment of malignant gliomas HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme The impact of GPCR structures on pharmacology and structure-based drug design Molecular therapy in head and neck oncology Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers Role of erlotinib in the management of pancreatic cancer. Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity A phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study Harnessing synthetic lethal interactions in anticancer drug discovery Targeted therapy in nonmelanoma skin cancers. Exploiting novel molecular targets in gastrointestinal cancers. Effects of the EGFR Inhibitor Erlotinib on Magnesium Handling EGFR(s) in aging and carcinogenesis of the gastrointestinal tract. Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity Systemic therapies in metastatic non-small-cell lung cancer with emphasis on targeted therapies: the rational approach The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition Rationale and clinical experience with epidermal growth factor receptor inhibitors in gynecologic malignancies Antitumor activity of the HER2 dimerization inhibitor pertuzumab on human colon cancer cells in vitro and in vivo EGFR activation increases parathyroid hyperplasia and calcitriol resistance in kidney disease Activator protein 2alpha mediates parathyroid TGF-alpha self-induction in secondary hyperparathyroidism

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 195 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software